Results 51 to 60 of about 2,055 (161)

Umfrage auf medinfo [PDF]

open access: yes, 2007
Ein Verweis auf eine medinfo-Umfrage, die sich diesmal mit dem Thema Stehen Sie vor dem Burn-out? beschäftigt, sich aber ausdrücklich nur an MitarbeiterInnen aus Medizinbibliotheken richtet, also nicht ...
Edlef Stabenau
core  

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy

open access: yesAmerican Journal of Hematology, Volume 99, Issue 5, Page 880-889, May 2024.
Abstract Axicabtagene ciloleucel (axi‐cel) in trials has demonstrated favorable efficacy compared with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) large B cell lymphoma (LBCL). Herein, we compared the real‐world effectiveness of axi‐cel with efficacy and effectiveness of chemoimmunotherapy (CIT) in ...
Matthew A. Lunning   +22 more
wiley   +1 more source

Nature‐versus‐nurture considered harmful: Actionability as an alternative tool for understanding the exposome from an ethical perspective

open access: yesBioethics, Volume 38, Issue 4, Page 356-366, May 2024.
Abstract Exposome research is put forward as a major tool for solving the nature‐versus‐nurture debate because the exposome is said to represent “the nature of nurture.” Against this influential idea, we argue that the adoption of the nature‐versus‐nurture debate into the exposome research program is a mistake that needs to be undone to allow for a ...
Caspar W. Safarlou   +3 more
wiley   +1 more source

Youth Med.Info: a case study in co-design of mental health medicines-information resources for children, young people and their parents/guardians

open access: yesBMJ Open
Objectives To address the lack of accurate and accessible mental health medicines-information resources for children, young people and their parents/guardians using design thinking to co-design free-to-use, video resources tailored to this audience ...
Aoife Carolan   +16 more
doaj   +1 more source

Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial

open access: yesMuscle &Nerve, Volume 69, Issue 1, Page 93-98, January 2024.
Abstract Introduction/Aims Delandistrogene moxeparvovec is indicated in the United States for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. Long‐term delandistrogene moxeparvovec microdystrophin protein (a shortened dystrophin that retains key ...
Jerry R. Mendell   +16 more
wiley   +1 more source

Wie wird GMS Medizin – Bibliothek – Information genutzt? Analyse der Zugriffszahlen einer Open Access-Zeitschrift / Usage of "GMS Medizin – Bibliothek – Information": analysis of usage data from an Open Access journal

open access: yesGMS Medizin – Bibliothek – Information, 2008
In 2006 the journal "MEDIZIN – BIBLIOTHEK – INFORMATION" changed from the internet platform of the "Arbeitsgemeinschaft für Medizinisches Bibliothekswesen" (AGMB) to the Open Access platform German Medical Science (GMS).
Bauer, Bruno
doaj  

ECTracker - An Efficient Algorithm for Haplotype Analysis and Classification [PDF]

open access: yes, 2007
Medinfo.
Wong, Limsoon   +8 more
core  

Referring quality assessment of primary health care for endocrinology in Rio Grande do Sul, Brazil [PDF]

open access: yes, 2015
Telemedicin
Grendene, Grabriela Monteiro   +3 more
core   +1 more source

Monitoring program for assessing population health and clinico-economical effectiveness of regional healthcare system

open access: yesКардиоваскулярная терапия и профилактика, 2009
The study analysed the information support for healthcare services in Omsk City adult population. The absence of adequate technical and technological means of healthcare information support could explain the low effectiveness of municipal healthcare in ...
S. V. Dobrykh   +3 more
doaj  

Home - About - Disclaimer - Privacy